عربي
English
Quick links
Related sites
Hotline for Health Services for Displaced Lebanese 1787
Hotline for the Patient Admission to Hospitals 01/832700
COVID-19 Vaccine Registration Form covax.moph.gov.lb
MoPH Hotline 1214
Are you a new member? Sign up now
 
Login area | Sign up
Forgot your password? Click here
Let us help you
Read about the latest topics.
Download the new version of the MOPH app 
 
 
 
Be Responsible
#Raise your voice
Send us any Fraudulent Action or Enquiry so we can ALL contribute to make a Difference

Acute Flaccid Paralysis

Generalities on Poliovirus
Agent Virus: poliovirus (genus enterovirus), with 3 serotypes: 1, 2 and 3
Incubation period 7-14 days (3-35 days)
Period of transmissibility 7-10 days before onset, up to 3-6 weeks after onset
Reservoir Humans
Modes of transmission -Person-to-person: faecal-oral route, and rarely pharyngeal
-Rarely through water and food
Clinical presentation -90-95% asymptomatic infection
-4-8% mild illness (influenza-like illness or gastro-intestinal illness)
-1-2% aseptic meningitis
-<1% paralytic poliomyeltis
Resources
Case definition - MOPH circular no 34 (2012)
- MOPH circular no 76 (2006)
Forms - General reporting form
- Specific reporting form
- Investigation form: data collection
- Investigation form: additional data
- Investigation form: specimen collection
- Investigation form: Rapid OPV3/IPV3 coverage survey
- Investigation form: Follow up at day 60
- Investigation form: Final classification
Guidelines Acute Flaccid Paralysis surveillance guideline: Ar, En, Fr
Data - AFP surveillance bulletin
    1
    2
    3
    4
    5
    6
    ...
    11
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
All
ATC Name B/G Ingredients Dosage Form Price
C08CA01 LOWRAC 5 G Amlodipine (besylate) - 5mg 5mg Capsule 362,837 L.L
N06AX21 LOXYT 60 G Duloxetine HCl - 60mg 60mg Capsule, delayed release 716,716 L.L
N06AX21 LOXYT 30 G Duloxetine HCl - 30mg 30mg Capsule, delayed release 716,716 L.L
A02BC03 LPZ-30 G Lansoprazole - 30mg 30mg Capsule, delayed release 360,150 L.L
L01EX08 LENVIMA B Lenvatinib - 10mg 10mg Capsule, hard L.L
L01EX08 LENVIMA B Lenvatinib - 4mg 4mg Capsule, hard L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 5mg 5mg Capsule, hard 71,647,217 L.L
L04AX04 LENOMA G Lenalidomide - 5mg 5mg Capsule, hard 68,908,116 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 10mg 10mg Capsule, hard 75,120,146 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard 14,449,637 L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard 15,241,884 L.L
L04AX04 LENALIDOMIDE SPC G Lenalidomide - 25mg 25mg Capsule, hard 87,161,381 L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard 15,343,847 L.L
C10BA06 LIPOCOMB B Rosuvastatin (calcium) - 10mg, Ezetimibe - 10mg Capsule, hard 1,811,500 L.L
C10BA06 LIPOCOMB B Rosuvastatin (calcium) - 20mg, Ezetimibe - 10mg Capsule, hard 1,811,500 L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.5mg 0.5mg Capsule, hard 32,406,715 L.L
L04AA27 LYXIA G Fingolimod Hydrochloride - 0.25mg 0.5mg Capsule, hard 32,406,715 L.L
L01EX08 LENVIMA B Lenvatinib - 4mg 4mg Capsule, hard 124,450,304 L.L
L01EX08 LENVIMA B Lenvatinib - 10mg 10mg Capsule, hard 124,450,304 L.L
L04AX04 LENOMA G Lenalidomide - 10mg 10mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 25mg 25mg Capsule, hard L.L
L04AX04 LENOMA G Lenalidomide - 15mg 15mg Capsule, hard L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07AB02 LOCOID B Hydrocortisone butyrate - 1mg/g 0.1% Cream 215,015 L.L
D07XC01 LOTRIDERM B Betamethasone (dipropionate) - 0.5mg/g, Clotrimazole - 10mg/g Cream 470,345 L.L
D01AC12 LOMEXIN B Fenticonazole nitrate - 2g/100g 2% Cream 758,029 L.L
D01AE15 LAMISIL B Terbinafine HCl - 10mg/g 1% Cream 616,824 L.L
D01AE15 LAMIFEN G Terbinafine HCl - 1% 1% Cream 350,743 L.L
D01AE15 LAMINOX G Terbinafine HCl - 10mg/g 10mg/g Cream 453,067 L.L
S01ED51 LOPROSTAN G Timolol - 5mg/ml, Latanoprost - 50?g/ml Drops 768,678 L.L
    1
    2
    3
    4
    5
    6
    ...
    11
Sitemap
© Copyrights reserved to Ministry of Public Health 2026